(Date:7/26/2008)...device giving patients freedom of movement, better...HealthDay News) -- An automated artificial kidney ...alysis patients what the insulin pump is to diabet...al kidney (AWAK) works better than conventional di...of Clinical and Experimental Nephrology . , "W...
(Date:7/25/2008)....Y., July 25 /PRNewswire-USNewswire/ -- Anthony Sh...ty Officer and Vice President,of Strategic Plannin..., a,national foundation committed to improving U.S... foundation,s Program on Health Care Quality,Impro...m.com/cgi-bin/prnh/20080725/DC28791LOGO ), Board...
(Date:7/25/2008)...ponse after antiretroviral therapy may be due to g...thDay News) -- A new study challenges the long-hel...the immune system,s ability to restore itself afte...retroviral therapy (HAART). , From 50 percent t...nfected with HCV. Intravenous drug use is the main...
(Date:7/25/2008)...ffers patients consumers tips and encourages them ...HARRISBURG, Pa., July 25 /PRNewswire-USNewswire/ -...supports "National Patient Safety Day" which,is a ...milies to,participate fully in their healthcare by... about their surgery or illness., "We understand ...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3(Date:7/24/2008)...re/ -- Headlines claiming "soy,products lower sper...ale,preliminary study that Dr. Jorge Chavarro, pu...recollected intake of soyfoods and not on,specific...ded by many,issues, thus I feel the results should...r. Tammy Hedlund, a researcher in prostate cancer,...
(Date:7/24/2008)... -- MacroChem Corporation (OTC,Bulletin Board: MAC...rial,involving 37 patients who completed a 48-week...y study of EcoNail, a topical antifungal,lacquer f...he composite,primary efficacy endpoint of the tria... (negative fungal culture and negative KOH) and cl...
(Date:7/23/2008)...y print edition of Clinical C... /- A Roche Diagnostics-sponsored,pil...pe natriuretic peptide,(NT-proBNP) confirms the po... in predicting the risk of cardiovascular adverse ...dal anti-inflammatory drugs of,the COX inhibitor c...
(Date:7/23/2008)...arma Inc., a company developing,breakthrough molec...graphy,(PET) market, announced positive Phase I re...cer for myocardial perfusion imaging. BFPET is,Flu...ete Phase I clinical,development., BFPET is a PET...in the,heart (myocardial perfusion). Myocardial pe...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Rheumatoid Arthritis Treatment Guidelines Updated 22828 1Rheumatoid Arthritis Treatment Guidelines Updated 22828 2Rheumatoid Arthritis Treatment Guidelines Updated 22828 3First Nursing Facility Installation of Masimo Patient SafetyNet 28TM 29 Goes Live With Remarkable Results 22825 1First Nursing Facility Installation of Masimo Patient SafetyNet 28TM 29 Goes Live With Remarkable Results 22825 2First Nursing Facility Installation of Masimo Patient SafetyNet 28TM 29 Goes Live With Remarkable Results 22825 3First Nursing Facility Installation of Masimo Patient SafetyNet 28TM 29 Goes Live With Remarkable Results 22825 4First Nursing Facility Installation of Masimo Patient SafetyNet 28TM 29 Goes Live With Remarkable Results 22825 5American Airlines Miles for the Cure Campaign Raises More Than 24600 000 for Susan G Komen for the Cure 28R 29 22822 1American Airlines Miles for the Cure Campaign Raises More Than 24600 000 for Susan G Komen for the Cure 28R 29 22822 2American Airlines Miles for the Cure Campaign Raises More Than 24600 000 for Susan G Komen for the Cure 28R 29 22822 3First CyberKnife System to be Installed in Canada 22819 1First CyberKnife System to be Installed in Canada 22819 2First CyberKnife System to be Installed in Canada 22819 3First CyberKnife System to be Installed in Canada 22819 4...ort Rationale for Targeting Pro-Inflammatory,Prote...e-FirstCall/ --,MedImmune, Inc. today announced th...ing a role for high mobility group box,protein-1 (...ology,of systemic autoimmune diseases such as syst...toid arthritis. Data to be,published in the May 20...
...pril 19, 2007 /PRNewswire-FirstCall/ --,VioQuest P...aceutical company focused on acquiring, developing...nounced data from its,preclinical studies of VQD- ...treatment of solid and hematologic tumors.,Pre-cli...2007,Annual Meeting of the American Association fo...
Other Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5...ly adjustable dispensing head, and disposable, pre...aralleled flexibility and cost-efficiency to micro... of its kind to offer fast dispensing of fluids in...lso offers the added benefit of being able to acco...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat
The Labcyte Echo 550 compound reformatter performs direct microplate-to-microplate transfers of droplets down to 5 nL using a new "touchless" transfer technology based on focused acoustic energy. Mon
Precise, nanoliter-volume liquid handling capability allows you to accurately dispense volumes as small as 5 nanoliters. Precision robotics and flexible software ensure accurate, repeatable X/Y motio
Medicine Products: